The client wanted to understand how oncologists view and use different treatment options for renal cell carcinoma (RCC), including the factors that influence their decisions when selecting treatments for patients. The study also sought to understand how awareness and perceptions of existing brands contribute to prescribing behaviour.
Borderless Access engaged with 500 medical oncologists and hematologists across the USA through hour-long research discussions. The study explored how physicians manage RCC treatment, their views of existing treatment brands, and the factors influencing their prescribing decisions. It also examined treatment needs across different stages of care, including neoadjuvant and metastatic settings.
Prescription decisions can be viewed through specific influencing drivers
The study compiled the factors influencing brand prescription, providing a clearer view of the attributes and considerations shaping oncologist choice in RCC treatment.
Awareness and usage were assessed separately
The research analyzed brand awareness against brand usage, helping distinguish familiarity with a brand from its actual place in treatment behaviour.
First- and second-line treatment offered different decision contexts
The study examined awareness and willingness to prescribe brands across first-line and second-line treatment, while also considering current and future therapy needs in neoadjuvant and metastatic settings.
Brand commitment does not necessarily indicate prescribing behaviour
The research generated real-time prescription insights around the relationship between brand commitment and actual prescription behaviour, providing a more nuanced view of brand performance.
The findings enabled the client’s marketing teams to customize brand messaging for oncologists around the key drivers of prescription. By connecting awareness, usage, perceptions, and prescribing behaviour, the study provided a stronger basis for brand communication.

© 2026 Borderless Access Pvt Ltd. All Rights Reserved.